Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
Background. Proximal spinal muscular atrophy 5q (5q-SMA) is a severe autosomal recessive neuromuscular disorder characterized by progressive flaccid paralysis and muscular atrophy caused by degeneration of α-motor neurons in the anterior horns of the spinal cord resulted from mutations in the SMN1 g...
Saved in:
| Main Author: | M. V. Panteleeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-12-01
|
| Series: | Русский журнал детской неврологии |
| Subjects: | |
| Online Access: | https://rjdn.abvpress.ru/jour/article/view/404 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with nusinersen as a pathogenetic therapy in adult patients with spinal muscular atrophy 5q in the Republic of Bashkortostan
by: S. V. Umutbaev, et al.
Published: (2023-03-01) -
Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)
by: K. D. Popov, et al.
Published: (2023-10-01) -
Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
by: Yiğithan Güzin, et al.
Published: (2024-11-01) -
Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort
by: Ömer Bektaş, et al.
Published: (2025-03-01) -
Nusinersen corrects L-arginine deficiency in the cerebrospinal fluid of patients with severe spinal muscular atrophy
by: Amber Hassan, et al.
Published: (2025-10-01)